XT
ADCT icon

XTX Topco’s ADC Therapeutics ADCT Stock Holding History

XTX Topco’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.3K Sell
17,422
-65,449
-79% -$258K ﹤0.01% 3247
2025
Q4 		$293K Sell
82,871
-8,708
-10% -$35.3K 0.01% 2095
2025
Q3 		$366K Buy
+91,579
New +$289K 0.02% 1345
2024
Q4 		– Sell
-115,073
Closed -$362K – 2229
2024
Q3 		$362K Buy
115,073
+58,210
+102% +$184K 0.03% 1064
2024
Q2 		$180K Buy
56,863
+32,034
+129% +$127K 0.02% 1278
2024
Q1 		$111K Sell
24,829
-18,821
-43% -$69.4K 0.02% 1344
2023
Q4 		$72.5K Sell
43,650
-23,401
-35% -$21.6K 0.02% 1177
2023
Q3 		$60.1K Sell
67,051
-139,316
-68% -$185K 0.01% 1257
2023
Q2 		$444K Sell
206,367
-59,892
-22% -$135K 0.08% 442
2023
Q1 		$519K Buy
266,259
+68,624
+35% +$253K 0.11% 269
2022
Q4 		$759K Buy
197,635
+187,267
+1,806% +$749K 0.16% 146
2022
Q3 		$50K Buy
+10,368
New +$75.1K 0.01% 1024

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

XTX Topco's ADCT Position: Q1 2026 in Review

XTX Topco reduced its ADC Therapeutics (ADCT) stake by 79% in Q1 2026, selling an estimated $258K and leaving 17,422 shares worth $65.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3247.

XTX Topco first reported a position in ADCT in Q3 2022 and has held it in 12 quarters since. The position peaked at $759K in Q4 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • XTX Topco held 17,422 shares of ADC Therapeutics worth $65.3K as of Q1 2026.
  • XTX Topco sold 65,449 ADC Therapeutics shares in Q1 2026, an estimated $258K.
  • ADC Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3247 holding.
  • XTX Topco first reported a position in ADC Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • XTX Topco's ADC Therapeutics position peaked at $759K in Q4 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.